HC Wainwright Increases Context Therapeutics (NASDAQ:CNTX) Price Target to $5.00

Context Therapeutics (NASDAQ:CNTX) had its target price lifted by investment analysts at HC Wainwright from $4.00 to $5.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 346.43% from the company’s current price.

Several other research analysts have also recently weighed in on CNTX. Guggenheim started coverage on Context Therapeutics in a report on Thursday, September 18th. They set a “buy” rating and a $5.00 target price on the stock. Cantor Fitzgerald started coverage on Context Therapeutics in a research report on Thursday, October 2nd. They set an “overweight” rating on the stock. D. Boral Capital reissued a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research note on Thursday, October 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Context Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $5.40.

Context Therapeutics Stock Performance

Shares of NASDAQ CNTX traded up $0.05 during mid-day trading on Thursday, reaching $1.12. The company’s stock had a trading volume of 198,791 shares, compared to its average volume of 477,134. The stock has a 50-day moving average of $1.07 and a two-hundred day moving average of $0.85. The stock has a market capitalization of $100.47 million, a P/E ratio of -4.67 and a beta of 1.94. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.10.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Analysts predict that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

An institutional investor recently raised its position in Context Therapeutics stock. Vanguard Group Inc. grew its holdings in Context Therapeutics Inc. (NASDAQ:CNTX) by 4.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,495,031 shares of the company’s stock after purchasing an additional 134,449 shares during the period. Vanguard Group Inc. owned approximately 3.90% of Context Therapeutics worth $3,387,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.